Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Non-Current Liabilities: 2016-2024

Historic Total Non-Current Liabilities for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $351.5 million.

  • Tg Therapeutics' Total Non-Current Liabilities rose 6.41% to $415.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.8 million, marking a year-over-year increase of 6.41%. This contributed to the annual value of $351.5 million for FY2024, which is 108.34% up from last year.
  • Per Tg Therapeutics' latest filing, its Total Non-Current Liabilities stood at $351.5 million for FY2024, which was up 108.34% from $168.7 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Total Non-Current Liabilities registered a high of $351.5 million during FY2024, and its lowest value of $105.4 million during FY2020.
  • Its 3-year average for Total Non-Current Liabilities is $218.3 million, with a median of $168.7 million in 2023.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first fell by 15.18% in 2020, then spiked by 108.34% in 2024.
  • Over the past 5 years, Tg Therapeutics' Total Non-Current Liabilities (Yearly) stood at $105.4 million in 2020, then spiked by 34.89% to $142.1 million in 2021, then fell by 5.19% to $134.7 million in 2022, then grew by 25.22% to $168.7 million in 2023, then skyrocketed by 108.34% to $351.5 million in 2024.